All GLG News Analyses Filed Under: Infectious Disease

Targeting a part of the influenza virus which does not mutate or a regular basis is a great idea. If the clinical data supports its efficacy, it would, indeed, be a novel approach to influenza vaccination.

If early results are confirmed, this vaccine will revolutionize influenza immunization          

A vaccine that combats all forms of flu-WOW. Let us see further results first.

In this small pilot study, R7128 at 1500 mg twice daily combined with Pegasys + ribavirin led to a rapid viral response (HVC RNA <15 IU/mL at week 4) in 85% of patients compared with  35% at 500 mg twice daily and 10% with Pegasys + ribavirin alone.  R7128 did not add much toxicity...

If you read the CDC analysis of January 2007, you would conclude that both the Merck and GSK vaccines offer little advantage to females under 30 years of age. Why the enormous campaign then by the marketers of these vaccines to get them in use? Since they only cover 70% of the high risk strains anyway,...

This drug which clearly focuses on antibiotic resistant strains  will be a welcome addition if it does not have significant side effects.

Ever had a sore arm for two days following a tetanus vaccine?

Successful completion of these studies in community acquired pneumonia and skin and soft tissue infection will hopefully lead to approval of an additional new drug active against drug resistant bacteria, such as MRSA.

The benefit/risk  ratio is so positive that this should be NO excuse not to use the vaccine.

Hospitals and physicians are under increasing pressure to follow benchmarks or be penalized. When this happens and when already lean payments are cut further, how can that lead to an increase in quality?